ACOG — Alpha Cognition Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1655923 ·
Last close
$7.92
Market Cap
$174.57M
52W High
$10.14
52W Low
$4.50
ADV30
104,282
Next earnings
2026-11-11
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 7,777,002 7,294,581 -6,430,704 -7,616,727 64,001,174 37,801,828 14,680,466
Jun 2026 6,092,974 5,701,917 -7,756,008 -8,789,740 64,519,883 41,384,287 11,558,134
Mar 2026 3,533,798 3,262,022 -8,096,227 -6,478,018 69,248,341 54,248,275 11,791,836
Dec 2025 2,793,076 2,540,827 -7,925,270 -6,856,306 79,730,235 66,046,789 17,200,060

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-30,853,299
Investing CF
$-6,228,498
Financing CF
$39,060,874
CapEx
$-6,228,498
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.84
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-112,374,533
Inventory
$6,394,817
Receivables
$5,648,873
ST Investments
—
EBIT TTM
$-29,079,491
Pretax Income TTM
$-23,442,139
Interest Exp TTM
$13,701
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$15,260,706
EBITDA
$-26,487,652
Free Cash Flow
$-28,530,086
Enterprise Value
$146,340,992
Total Cash
$41,384,288
Total Debt
$0
Shares Out
22,041,337
Trailing EPS
$-1.32
Book Value
$2.87
ROE
-49.5%
ROA
-30.4%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 10,220,275 -22,579,594 -20,669,875 79,730,235 17,200,060 62,530,175 -20,380,367
Dec 2024 0 -11,548,636 -14,788,727 50,736,938 11,642,111 39,094,827 -7,755,654
Dec 2023 0 -9,617,813 -13,763,658 2,452,170 7,155,865 -4,703,695 -8,799,565
Dec 2022 0 -13,465,624 -12,114,698 2,950,951 4,271,128 -1,320,177 -9,241,650
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$15,260,706
NetIncome TTM
$-23,442,138
OpCashFlow TTM
—
Assets (Latest)
$64,519,883
Forward EPS
$-0.56

Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)

max pain strike: $7.50 · spot: $8.60 · call volume: 28 · put volume: 3
Expected Move to 2027-02-19: ±$3.65 (42.44%) — implied range $4.95 – $12.25 · ATM straddle on $7.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
IPHYF Innate Pharma SA $168.56M $1.51 —
PALI PALISADE BIO, INC. $181.07M $1.01 —
ARTV Artiva Biotherapeutics, Inc. $190.81M $3.86 —
CGEN COMPUGEN LTD $191.34M $2.02 —
IKT Inhibikase Therapeutics, Inc. $193.57M $1.38 —

News headlines (Yahoo Finance, 1h cache)

Wall Street Analysts Predict an 119.28% Upside in Alpha Cognition Inc. (ACOG): Here's What You Should Know
2026-11-16 13:55 · Yahoo
Alpha Cognition Announces Publication of U.S. Patent Application for Benzgalantamine for Treating Persistent Post-Concussion Symptoms
2026-11-16 13:30 · Yahoo
Alpha Cognition (ACOG) Q3 2026 Earnings Call Transcript
2026-11-12 02:03 · Yahoo
Alpha Cognition Inc. Common Stock Q3 2026 Earnings Call Summary
2026-11-12 01:24 · Yahoo
What Alpha Cognition (ACOG) Said on Its Q3 Earnings Call
2026-11-11 23:13 · Yahoo
Alpha Cognition Inc. (ACOG) Reports Q3 Loss, Beats Revenue Estimates
2026-11-11 21:20 · Yahoo
Alpha Cognition Inc. Reports Third Quarter 2026 Financial Results and Provides Operational Update
2026-11-11 21:05 · Yahoo
Alpha Cognition Strengthens Its Board of Directors with Appointment of Caren Deardorf
2026-11-09 13:30 · Yahoo
Alpha Cognition to Participate in Upcoming Investor Events
2026-11-06 20:00 · Yahoo
Alpha Cognition to Report Third Quarter 2026 Financial Results and Provide Business Update
2026-11-02 21:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.